NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia.

Autor: Shang CY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Bei LY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Wu JZ; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Sheng HR; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Yin H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Liang JH; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Wang L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Li JY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Li Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. cph7707@126.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. cph7707@126.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. cph7707@126.com., Xu W; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. xuwei10000@hotmail.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. xuwei10000@hotmail.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. xuwei10000@hotmail.com.

Publikováno v: Annals of hematology [Ann Hematol] 2024 Mar; Vol. 103 (3), pp. 833-841. Date of Electronic Publication: 2023 Nov 23.